How do drug users define their progress in harm reduction programs? Qualitative research to develop user-generated outcomes.

Harm Reduct J

New York Harm Reduction Educators, Inc (NYHRE), 903 Dawson St, Bronx, New York 10459.

Published: August 2004

BACKGROUND: Harm reduction is a relatively new and controversial model for treating drug users, with little formal research on its operation and effectiveness. In order to advance the study of harm reduction programs and our understanding of how drug users define their progress, qualitative research was conducted to develop outcomes of harm reduction programming that are culturally relevant, incremental, (i.e., capable of measuring change), and hierarchical (i.e., capable of showing how clients improve over time). METHODS: The study used nominal group technique (NGT) to develop the outcomes (phase 1) and focus group interviews to help validate the findings (phase 2). Study participants were recruited from a large harm-reduction program in New York City and involved approximately 120 clients in 10 groups in phase 1 and 120 clients in 10 focus groups in phase 2. RESULTS: Outcomes of 10 life areas important to drug users were developed that included between 10 to 15 incremental measures per outcome. The outcomes included ways of 1) making money; 2) getting something good to eat; 3) being housed/homeless; 4) relating to families; 5) getting needed programs/benefits/services; 6) handling health problems; 7) handling negative emotions; 8) handling legal problems; 9) improving oneself; and 10) handling drug-use problems. Findings also provided insights into drug users' lives and values, as well as a window into understanding how this population envisions a better quality of life. Results challenged traditional ways of measuring drug users based solely on quantity used and frequency of use. They suggest that more appropriate measures are based on the extent to which drug users organize their lives around drug use and how much drug use is integrated into their lives and negatively impacts other aspects of their lives. CONCLUSIONS: Harm reduction and other programs serving active drug users and other marginalized people should not rely on institutionalized, provider-defined solutions to problems in living faced by their clients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC516446PMC
http://dx.doi.org/10.1186/1477-7517-1-8DOI Listing

Publication Analysis

Top Keywords

drug users
28
harm reduction
20
drug
10
users define
8
define progress
8
reduction programs
8
develop outcomes
8
120 clients
8
groups phase
8
users
6

Similar Publications

StackDILI: Enhancing Drug-Induced Liver Injury Prediction through Stacking Strategy with Effective Molecular Representations.

J Chem Inf Model

January 2025

Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, 2001 Longxiang Road, 518172 Shenzhen, China.

Drug-induced liver injury (DILI) is a major challenge in drug development, often leading to clinical trial failures and market withdrawals due to liver toxicity. This study presents StackDILI, a computational framework designed to accelerate toxicity assessment by predicting DILI risk. StackDILI integrates multiple molecular descriptors to extract structural and physicochemical features, including the constitution, pharmacophore, MACCS, and E-state descriptors.

View Article and Find Full Text PDF

Montelukast, a leukotriene receptor antagonist (LTRA) approved for the treatment of asthma and allergic rhinitis, is widely used, though real-world data on its application in asthma management remain limited. This registry-based study evaluated the use of montelukast in adult asthma patients, examining demographic and disease characteristics, asthma control status, asthma phenotypes, presence of atopy, and treatment regimens. Among 2053 patients analyzed, 61.

View Article and Find Full Text PDF

Public Health.

Alzheimers Dement

December 2024

Eisai Inc., Woodcliff Lake, NJ, USA.

Background: This study aims to describe usage patterns and risk factors associated with anticoagulant therapy in patients with mild cognitive impairment (MCI) or Alzheimer's disease (AD).

Methods: The United States Medicare claims database (2008- 18) was used to identify patients aged ≥65 years with MCI or AD and to evaluate their anticoagulant use from 2016- 17. A random sample of new anticoagulant users (n = 21,069) was selected.

View Article and Find Full Text PDF

Public Health.

Alzheimers Dement

December 2024

University of Maryland School of Public Health, College Park, MD, USA.

Background: Escalating drug costs are likely to disproportionately burden individuals with Alzheimer's disease and related dementias (ADRD) as they often have multiple chronic conditions (MCC). This study aimed to estimate the incremental total and out-of-pocket (OOP) drug costs associated with ADRD and MCC across the drug cost distributions.

Method: The study used a nationally representative cross-sectional dataset from 2003 to 2021 Medical Expenditure Panel Survey.

View Article and Find Full Text PDF

Public Health.

Alzheimers Dement

December 2024

University of Haifa, Haifa, Israel.

Background: Cannabis use has increased substantially in recent years, for both recreational and medicinal purposes. While the deleterious effects of cannabis use during adolescence on brain health are well acknowledged, long-term implications of cannabis use on brains of older adults remain unknown. We explored the associations between past and current cannabis use and volumetric brain MRI measures in older participants of the UK biobank.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!